Emerging Agents Impacting Future Treatment Strategies in AML
Chapter 1: Current Treatment Landscape in AML
Editor’s Note: Following the filming of this activity, two therapies have received approval by the U.S. Food and Drug Administration (FDA). On August 1, 2017, the FDA granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. On August 3, 2017, the FDA approved CPX-351 for the treatment of adult patients with newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Please complete Pre-test
Chapter 1 of 3
Release Date: May 31, 2017
Expiration Date: May 31, 2018
Expected time to complete this activity as designed: 45 minutes
There are no fees for participating in or receiving credit for this online activity.
The treatment landscape for acute myeloid leukemia (AML) is rapidly evolving due to a multitude of investigational therapies across various patient populations. Recently, there have been a number of agents designated as breakthrough therapy by the Food and Drug Administration (FDA), including venetoclax, CPX-351, midostaurin and pracinostat, in combination with azacitidine. In addition, there are a number of novel agents in late-stage clinical development, reinforcing the potential availability of new treatment options in the near future. In this activity, Dr. Desai will discuss novel therapies being studied in clinical trials for different patient populations, as well as the future direction of treatment strategies in AML.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Describe the mechanism of action and therapeutic rationale for novel agents under investigation for the treatment of patients with acute myeloid leukemia (AML)
- Summarize the key efficacy and safety data from clinical trials investigating novel therapies for patients with AML
Emerging Agents Impacting Future Treatment Strategies in AML – Pinkal Desai, MD, MPH
Instructions for Participation and Credit
This activity is eligible for credit through May 31, 2018. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Pinkal Desai, MD, MPH
Assistant Professor of Medicine
Weill Cornell Medical College
Assistant Attending Physician
New York-Presbyterian Hospital
New York, New York
Dr. Pinkal Desai received her MBBS at Byram Jeejeebhoy Medical College in India, and her MPH at the University of Alabama at Birmingham School of Public Health. Following her residency at Wayne State University, Detroit Medical Center, she underwent fellowship training in hematology-medical oncology at Providence Hospital Medical Center, serving as chief fellow. Dr. Desai is an Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at the New York-Presbyterian Hospital. She was recruited to serve in the Leukemia Program to develop a clinical practice devoted to leukemia, myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN) where she will also develop the clinical and translational research protocols and projects.
Dr. Desai is a member of the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has served on the ASCO University Committee. She has been published in Cancer Epidemiology Biomarkers Prevention and International Journal of Molecular Epidemiology and Genetics. In addition, Dr. Desai is the lead author and co-author on numerous Women’s Health Initiative (WHI) paper proposals and has presented abstracts at national meetings.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Helsinn, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.
©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.75 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-150-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Pinkal Desai has disclosed no relevant financial relationships.
Planning Committee Disclosures
The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.